Benjamin C. Powers, MD
I earned my medical degree from the University of Kansas School of Medicine, then completed internal medicine residency at Loyola University Medical Center back in Chicago. I returned to Kansas City again for my hematology/oncology fellowship at the University of Kansas Medical Center.
I am certified by the American Board of Internal Medicine in hematology and medical oncology. In my clinical practice, I have subspecialized further into medical management of bone and soft tissue tumors, while also being involved in ongoing education/coaching/mentoring of first and second year medical students. I have a lovely wife and three active sons, and enjoy outdoor sports, barbecuing, travelling and reading.
Education and Training
- BS, Bachelor of Science, University of Notre Dame, Notre Dame, IN
- MD, Doctor of Medicine, University of Kansas Medical Center
- Residency, Internal Medicine, Loyola University Medical Center , Maywood , IL
- Residency, Loyola University , Maywood, IL
- Clinical Fellowship, Hematology/Oncology, Kansas University Medical Center, Kansas City, KS
Licensure, Accreditations & Certifications
- American Board of Internal Medicine, American Board of Internal Medicine
- American Board of Internal Medicine, Subspecialty Hematology, American Board of Internal Medicine
- American Board of Internal Medicine, Subspecialty Medical Oncology, American Board of Internal Medicine
- Kansas Board of Healing Arts, Kansas
- Missouri Board of Registration for the Healing Arts, Missouri
- Connective Tissue Oncology Society, Member, 2016 - Present
Clinical research into bone and soft tissue tumors!
I have presented at least one poster annually at the international annual Connective Tissue Oncology Society meetings from 2018 - current.
We took part in cohort 51, SWOG 1609, which has helped make immunotherapy an option for refractory angiosarcomas.
We have active trials for subtypes of sarcomas including chondrosarcoma, clear cell sarcomas, high grade sarcomas of extremity, GIST refractory to imatinib, and even a locally aggressive tumor called pigmented villonodular synovitis. Also participate in trials based on genetic alterations (i.e. IDH mutations, NF1 alterations...)